Andrew Huberman interviews Dr. Natalie Crawford about fertility, ovarian reserve, hormone health, and practical steps women can take to improve reproductive outcomes and long-term health. The discussion strongly emphasizes AMH testing, cycle/ovulation tracking, inflammation reduction, and avoiding certain exposures like cannabis, smoking, and some endocrine disruptors.
Watch on YouTube ›Get the market thesis, key claims, assets, contradictions, and follow-up questions from any financial video — then unlock a version personalized to your portfolio, watchlist, and favorite speakers.
This is a long-form interview focused on women’s fertility and hormone health as a lens on overall health and longevity. Dr. Natalie Crawford argues that fertility is not just about becoming pregnant; it is a readout of ovarian function, hormonal signaling, metabolic health, and inflammatory burden. A central thesis is that women should not wait for infertility to be diagnosed before getting useful information: she repeatedly advocates for proactive testing, especially AMH, and for tracking ovulation rather than just counting periods. Crawford explains the biology of egg reserve and egg quality in accessible terms, describing the “vault” of eggs, how AMH reflects ovarian reserve rather than egg quality, and why age and metabolic health affect chromosome integrity and mitochondrial function in eggs. …
Immediate setup: if pregnancy is a near-term goal, the actionable move is to get data fast—AMH, ovulation timing, and semen analysis if needed—while avoiding obvious fertility headwinds like cannabis, nicotine, and NSAIDs around ovulation. The near-term risk is lost time from assuming regular periods or prior pregnancy guarantees current fertility.
Over the next few months, the likely path is more individualized fertility planning: lifestyle optimization, earlier workups for low reserve or irregular ovulation, and selective use of preservation or treatment tools. The view weakens if testing keeps showing normal reserve and regular ovulation without conception, which would shift attention toward partner factors or structural causes.
The structural thesis is that reproductive medicine is moving from reactive treatment to proactive optimization, with fertility functioning as a longevity and metabolic-health marker. Over time, wider access to testing, preservation, and patient education could normalize earlier intervention and reduce the old 'fail first' model.
Every woman who may want children someday should get an AMH test.
Crawford repeatedly says AMH is important, inexpensive, and should be checked proactively rather than only after infertility is diagnosed.
AMH reflects ovarian reserve, not egg quality.
She distinguishes the two directly and explains AMH as a count of eggs outside the ovarian vault.
Fertility is a health marker tied to metabolic health, inflammation, and long-term disease risk.
She links infertility with metabolic syndrome, cancer, heart attack, stroke, and early death as warning signs rather than direct causes.
How should people think about fertility as a marker of general health, even if they are unsure about having children?
Fertility is framed as a broad health marker, not just the ability to get pregnant. It reflects hormonal, cellular, metabolic, and ovarian function, and infertility can be an early warning sign for inflammation or insulin resistance linked to later health risks.
How should women in perimenopause or after menopause use menstrual history as a health indicator?
As long as a woman is still menstruating, she is ovulating and periods remain informative about hormonal health, especially in perimenopause. After menopause, the ovaries no longer respond to brain signals and metabolic health changes, but earlier cycle patterns can still offer clues about current health.
What is the current thinking on when women can start hormone replacement therapy?
She says the field is moving toward allowing hormone replacement therapy earlier, including during perimenopause, rather than forcing women to wait until a full year without periods. She argues that delaying treatment until after clear ovarian failure is a disservice to women.
Unlock the full claims, asset map, scores, related transcripts, follow-up questions, and AI chat — shaped around your portfolio, watchlist, favorite speakers, and risks.
